HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Northeastern Section of the American Urological Association Meeting on September 18. The paper is authored by leading clinical research investigators participating in the U.S. clinical trials of NX-1207.
